CHUGAI PHARMACEUTICAL CO., LTD.

Japan's lung cancer market is projected to reach US$ 9,376.83 million by 2032, driven by an aging population, advancements in precision medicine, and government initiatives. Key trends include increased use of immunotherapies, personalized medicine, and rising cases among non-smokers. Challenges include high treatment costs and late diagnosis. Major players like AstraZeneca, Roche, and Merck & Co. dominate with targeted therapies and immunotherapies. Non-Small Cell Lung Cancer (NSCLC) remains the largest contributor to market revenue.

Roche to present over 40 abstracts on nine blood disorders at the 66th ASH Annual Meeting, highlighting long-term follow-up data for Polivy®, Lunsumio®, and Columvi®, and new combination data, reinforcing commitment to advancing lymphoma patient outcomes.

Chugai Pharmaceutical collaborates with Eli Lilly and Roche on obesity treatments, focusing on orforglipron, an oral medicine to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Chugai Pharmaceutical filed for Tecentriq approval in Japan for relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type (R/R ENKL), based on a phase II study showing 53.8% response rate. If approved, Tecentriq would be the first immune checkpoint inhibitor for R/R ENKL, a disease with poor prognosis and no standard treatment.

Roche announced phase III INAVO120 trial results for Itovebi in NEJM, showing 57% reduction in HR-positive, HER2-negative breast cancer progression or death risk with median progression-free survival of 15.0 months vs. 7.3 months. FDA approved Itovebi as first-line treatment for PIK3CA-mutated cases.

Japan's bioanalytical testing services market valued at US$ 75.6 million in 2023, projected to reach US$ 203.0 million by 2032, driven by precision medicine, biologics, and biosimilars. The market's growth is supported by chronic diseases, aging population, and government investments in biopharmaceutical research. Key segments include small molecule bioanalysis (53.7% market share) and oncology applications (32.2% revenue). Technological advancements and regulatory streamlining are expected to further boost market expansion.

Roche's VENTANA CLDN18 (43-14A) RxDx Assay is the first FDA-approved IHC companion diagnostic for identifying CLDN18 protein expression in gastric/GEJ adenocarcinoma, aiding in treatment eligibility for Astellas' VYLOY (zolbetuximab).

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.